HDL-C in Cardiac Syndrome X

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

710 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-03-31

Study Completion Date

2014-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

High density lipoprotein cholesterol (HDL-C) is in the centrum of the process of reverse cholesterol transport from peripheral cells to the liver\[10\]. HDL-C promotes endothelial generation of nitric oxide (NO) and improves endothelial function and arterial vasoreactivity\[11\]. In several studies, lower HDL-C level was reported to be associated with increased coronary artery disease (CAD) risk\[12-14\]. HDL-C also has anti- inflammatory and anti-oxidant activities\[15,16\]. Concerning anti-inflammatory activity, HDL-C inhibits the activation of monocytes/macrophages and neutrophils\[17,18\] and inhibits the expression of endothelial adhesion molecules, such as vascular cell adhesion molecule-1 (VCAM-1) and E-selectin\[15\].

In this study we aimed to investigate the relation of HDL-C level with systemic inflammatory markers in patients with cardiac syndrome X (CSX).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Association Between Different Monocyte Subsets and Coronary Collateral Development

NCT01356836

Coronary Artery Disease Coronary Ischemia

COMPLETED

Decrease in Paraoxonase Enzyme Level and Myocardial İnfarction

NCT04243876

Myocardial Infarction High-Density Lipoid Deficiency

COMPLETED

Impact of Endothelial and Leukocyte Senescence in Circulatory Shock States

NCT03559569

Shock Cardiovascular Diseases Infection

RECRUITING

Release of Epoxyeicosatrienoic Acids From Erythrocytes During the Use of Extracorporeal Procedures (Heart-lung Machine)

NCT04598360

Coronary Arteriosclerosis Valve Heart Disease

COMPLETED NA

Coronary Chronic Total Occlusion and Oxidative Balance

NCT04754880

Progression of Atherosclerotic Plaque Coronary Artery Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiovascular Diseases Heart Diseases Myocardial Ischaemia Unstable Angina Microvascular Angina

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CROSSOVER

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cardiac Syndrome X

No interventions assigned to this group

Control Group

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must be able to get exercise stress test
* Must be able to have coronary angiography
* Clinical diagnosis of typical anginaduring rest or effort
* Abnormal test result for exercise ECG or myocardial perfusion scintigraphy
* Must have of angiographically normal epicardial coronary arteries

Exclusion Criteria

* Patients with valvular heart disease (mitral stenosis and moderate to severe mitral regurgitation
* Patients with moderate to severe aortic stenosis and regurgitation including mitral annular calcification)
* Patients with heart failure (left ventricular ejection fraction \<50%)
* Patients with congenital heart disease, cardiomyopathy, left ventricular hypertrophy, right ventricular hypertrophy
* Patients with cardiac surgery
* Patients with thyroid disease
* Patients with anemia
* Patients with pulmonary diseases
* Patients with infectious diseases (locally or systemic)

Minimum Eligible Age

47 Years

Maximum Eligible Age

58 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes